Authors
Latest:
Safety Findings Appear Encouraging for REGN5458 in Relapsed/Refractory MyelomaDeepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.
Latest:
Unmet Needs and Future Treatment Approaches in Gastric CancerDeidre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses unmet needs as well as future treatment approaches for patients with gastric cancer.
Latest:
Dr. Deirdre Cohen on When to Treat Gastric Cancer Patients With ImmunotherapiesDr. Deirdre Cohen talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers.
Latest:
The Treatment of Patients With Bone Health IssuesDenise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, on the treatment of patients with breast cancer with bone health issues.
Latest:
Dr. Yardley Offers Advice to Community Oncologists on Managing PatientsDenise Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, offers advice to community oncologists on managing patients.
Latest:
More Endpoints Not Necessarily Merrier in NSCLC Drug TrialsThe US Food and Drug Administration (FDA) released new guidance on the use of alternative endpoints, in addition to overall survival (OS), for clinical trials of non–small cell lung cancer (NSCLC) therapies.
Latest:
Radiation Therapy for DCIS Does Not Increase Risk of Cardiovascular DiseaseWomen with DCIS treated with radiation therapy had no increased risk of cardiovascular disease compared with women in the general population or women with DCIS treated with surgery.
Latest:
Improving Radiotherapy Responses in Head and Neck Cancer With Galectin-1Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers.
Latest:
Current Treatment Landscape for Pancreatic CancerDiane Simeone, MD, director of the Pancreatic Cancer Center and associate director of Translational Research at NYU Langone’s Perlmutter Cancer Center, discusses the current state of the pancreatic cancer treatment paradigm. She says it is a very exciting time for this field as there is a large body of researchers now involved.
Latest:
Bendamustine/Rituximab as Induction Therapy in MCL<br /> Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma. <br />
Latest:
Prognostic Factors Influencing Local Control in Ewing SarcomaDimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognostic factors influencing local control in Ewing sarcoma.
Latest:
Dr. Dirk Arnold on Sirflox and its Effect on Liver MetastasesDirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Latest:
Combining Targeted Therapy With Checkpoint Blockade for the Treatment of MelanomaDirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the combination of targeted therapy and checkpoint blockade for the treatment of melanoma.
Latest:
Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung CancerDiwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
Latest:
The Role of In Situ Tumor VaccinationDmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of in situ tumor vaccination across various types of cancer.
Latest:
The Future of XMT-1536 in Ovarian Cancer and NSCLCDon Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).
Latest:
An Overview of Ovarian Cancer ScreeningDon S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an overview of screening for ovarian cancer.
Latest:
PARP Inhibitors for Ovarian CancerDonna McNamara, MD, discusses PARP inhibitors for the treatment of ovarian cancer.
Latest:
The Need to Lower Healthcare CostsDonna Shalala, PhD, President, University of Miami, discusses the need to bring healthcare costs down at the 2013 Miami Breast Cancer Conference.
Latest:
Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian CancerDouglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the efficacy of niraparib (Zejula) on progression-free survival in patients with recurrent ovarian cancer with partial response to the last platinum-based chemotherapy.
Latest:
Long-Term Results of Post-Prostatectomy RadiotherapyDouglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Latest:
Tremblay's Approach to Cytoreduction Across MPNsDouglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia and polycythemia vera.
Latest:
Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast CancerDouglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial.
